Amino acid metabolic processes in the temporal lobes assessed by proton magnetic resonance spectroscopy (^1H MRS) in children with Down syndrome

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Pharmacological Reports

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1734-1140(10)70369-8PMID 21273664
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological intervention of hippocampal CA3 NMDA receptors impairs acquisition and long-term memory retrieval of spatial pattern completion task.

  2009cited by this paper
• Cyclooxygenase inhibitors: a novel direction for Alzheimer's management.

  2008cited by this paper
• The epidemiology of Alzheimer disease in intellectual disability: results and recommendations from an international conference.

  2007cited by this paper
• Antioxidant enzymes and lipid peroxides in children with Down syndrome

  2007cited by this paper
• Brain metabolic profile obtained by proton magnetic resonance spectroscopy HMRS in children with Down syndrome.

  2007influential reference
• Neurophysiologic and neuroimaging studies of brain plasticity in children with spastic cerebral palsy.

  2006cited by this paper
• Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis.

  2005cited by this paper
• Erythrocyte antioxidant system in Down syndrome.

  2005cited by this paper
• Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study.

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Proton magnetic resonance spectroscopy in children with spastic diplegia

  2004cited by this paper
• N‐Acetylaspartate: a literature review of animal research on brain ischaemia

  2004cited by this paper
• A voxel-based morphometric study of nondemented adults with Down Syndrome

  2003cited by this paper
• 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease

  2002cited by this paper
• Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease

  2001cited by this paper
• Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy in Dementias

  2001influential reference
• Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD

  2000cited by this paper
• In vivo brain myo-inositol levels in children with Down syndrome.

  1999influential reference
• High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study.

  1999influential reference
• A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression.

  1999cited by this paper
• Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging

  1997cited by this paper
• Reduced N-acetylaspartate in the brain observed on in vivo proton magnetic resonance spectroscopy in patients with mental retardation.

  1995cited by this paper
• Modulation of learning processes by ionotropic glutamate receptor ligands.

  1995influential reference
• Role of Increased Cerebral myo‐Inositol in the Dementia of Down Syndrome

  1995influential reference
• Magnetic resonance imaging analysis of age‐related changes in the brains of individuals with Down's syndrome

  1994cited by this paper
• Psychiatric Morbidity in Older People with Moderate and Severe Learning Disability

  1993cited by this paper
• The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization.

  1993influential reference
• In vivo proton magnetic resonance spectroscopy study on premature aging in adult Down's syndrome.

  1993cited by this paper
• Lipid peroxidation in experimental and clinical epilepsy and the effects of sodium valproate and vitamin E on these processes

  1992cited by this paper
• Alzheimer's disease and Down's syndrome

  1988cited by this paper

• Adults with down syndrome exhibit altered somatosensory cortical inhibition

  2025cites this paper
• Alterations in aperiodic and periodic EEG activity in young children with Down syndrome

  2024cites this paper
• Neurodevelopmental Abnormalities in Down Syndrome: Assessing Structural and Functional Deficits

  2024cites this paper
• Neuronal oscillations in cognition: Down syndrome as a model of mouse to human translation

  2024cites this paper
• Alterations in aperiodic and periodic EEG activity in young children with Down syndrome

  2024cites this paper
• Bio-Metal Dyshomeostasis-Associated Acceleration of Aging and Cognitive Decline in Down Syndrome.

  2023cites this paper
• Understanding the genetic mechanisms and cognitive impairments in Down syndrome: towards a holistic approach

  2023cites this paper
• Brain metabolic profile assessed by magnetic resonance spectroscopy in ‎‎children with Down syndrome: Relation to intelligence quotient

  2023cites this paper
• Brain circuit pathology in Down syndrome: from neurons to neural networks

  2022cites this paper
• Edited magnetic resonance spectroscopy in the neonatal brain

  2021cites this paper
• Neuropsychiatric Symptoms of Alzheimer’s Disease in Down Syndrome and Its Impact on Caregiver Distress

  2021cites this paper
• What We Should Not Forget about Down Syndrome

  2021cites this paper
• Neurometabolite mapping highlights elevated myo-inositol profiles within the developing brain in down syndrome

  2020cites this paper
• Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.

  2020cites this paper
• Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

  2019cites this paper
• Down syndrome: Neurobiological alterations and therapeutic targets

  2019cites this paper
• 1H-MRS Metabolites in Adults with Down Syndrome: Effects of Dementia

  2018cites this paper
• Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis

  2018influential citation
• GABAergic over‐inhibition, a promising hypothesis for cognitive deficits in Down syndrome

  2018cites this paper
• Characterising impaired synaptic plasticity and network function in a mouse model of Alzheimer’s Disease in Down Syndrome

  2017cites this paper
• The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome

  2017cites this paper
• Combinatorial Gene Effects on the Neural Progenitor Pool in Down Syndrome

  2017cites this paper
• Plasma Amyloid Beta 1-42 and DNA Methylation Pattern Predict Accelerated Aging in Young Subjects with Down Syndrome

  2016cites this paper
• Problem behaviors , intelligent quotient , and brain proton magnetic resonance spectroscopy in girls with idiopathic central precocious puberty

  2016cites this paper
• 1H-MRS metabolites in adults with Down syndrome: Effects of dementia

  2016cites this paper
• Cerebal overinhibition could be the basis for the high prevalence of epilepsy in persons with Down syndrome.

  2015cites this paper
• Abnormal relationship between GABA, neurophysiology and impulsive behavior in neurofibromatosis type 1.

  2015cites this paper
• Delays in Motor Development in Children with Down Syndrome

  2015cites this paper
• Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy (1H MRS)

  2014cites this paper
• One-carbon metabolism in neurodevelopmental disorders: using broad-based nutraceutics to treat cognitive deficits in complex spectrum disorders.

  2014cites this paper
• Reducing GABAergic inhibition restores cognitive functions in a mouse model of Down syndrome.

  2014cites this paper
• Initial response to antiepileptic drugs in patients with newly diagnosed epilepsy.

  2014cites this paper
• Treating enhanced GABAergic inhibition in Down syndrome: use of GABA α5-selective inverse agonists.

  2014cites this paper
• In vivo 1H MRS study in microlitre voxels in the hippocampus of a mouse model of Down syndrome at 11.7 T

  2014cites this paper
• Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives

  2014cites this paper
• Reduced subcortical glutamate/glutamine in adults with autism spectrum disorders: a [1H]MRS study

  2014cites this paper
• Reduced subcortical glutamate/glutamine in adults with autism spectrum disorders: a [1H]MRS study

  2013cites this paper
• GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact.

  2013cites this paper
• A volumetric magnetic resonance imaging study of brain structures in children with Down syndrome.

  2011cites this paper
• Neurophysiologic, neuroimaging and biochemical studies in children and adolescents with Down syndrome

  2011cites this paper
• Combinatorial Gene Effects on the Neural Progenitor Pool in Down Syndrome

  2011cites this paper
• Metabolic and Vascular Imaging Biomarkers in Down Syndrome Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis Pathogenesis

  year unknowncites this paper
• World Journal of Clinical Pediatrics

  year unknowncites this paper